249 related articles for article (PubMed ID: 23187848)
1. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
Goff SL; Chabot JA
Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
Winner M; Goff SL; Chabot JA
Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054
[TBL] [Abstract][Full Text] [Related]
3. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
4. New developments in the management of borderline resectable pancreatic cancers.
Goodman MD; McPartland S; Huber K; Saif MW
JOP; 2013 Jul; 14(4):334-6. PubMed ID: 23846921
[TBL] [Abstract][Full Text] [Related]
5. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
6. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
[TBL] [Abstract][Full Text] [Related]
7. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
8. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer.
Chawla A
J Surg Oncol; 2021 May; 123(6):1423-1431. PubMed ID: 33831254
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
Hoffe S; Rao N; Shridhar R
Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
[TBL] [Abstract][Full Text] [Related]
10. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
11. [Borderline resectable pancreatic cancer - a definition and effective treatment strategy].
Yokoyama Y; Ebata T; Igami T; Sugawara G; Takahashi Y; Kokuryo T; Tsunoda N; Fukaya M; Uehara K; Itatsu K; Yoshioka Y; Nagino M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):337-41. PubMed ID: 22421757
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].
Motoi F; Kawaguchi K; Aoki T; Kudo K; Yabuuchi S; Fukase K; Mizuma M; Sakata N; Otsutomo S; Morikawa T; Hayashi H; Nakagawa K; Okada T; Yoshida H; Naitoh T; Katayose Y; Egawa S; Unno M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1632-6. PubMed ID: 24393872
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant strategy as initial treatment in resectable pancreatic cancer: concrete evidence of benefit.
DE Felice F; Musio D; Raffetto N; Tombolini V
Anticancer Res; 2014 Sep; 34(9):4673-6. PubMed ID: 25202043
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
15. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.
Mornex F; Girard N; Delpero JR; Partensky C
Semin Radiat Oncol; 2005 Oct; 15(4):226-34. PubMed ID: 16183476
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy in resectable pancreatic cancer: a critical review.
Belli C; Cereda S; Anand S; Reni M
Cancer Treat Rev; 2013 Aug; 39(5):518-24. PubMed ID: 23122322
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma in 2006].
Deberne M; Huguet F; Le Scodan R; Hammel P; Andre T
Bull Cancer; 2007 Jan; 94(1):72-80. PubMed ID: 17237007
[TBL] [Abstract][Full Text] [Related]
18. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies.
Festa V; Andriulli A; Valvano MR; Uomo G; Perri F; Andriulli N; Corrao S; Koch M
JOP; 2013 Nov; 14(6):618-25. PubMed ID: 24216547
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
